Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal Cancer
Status:
Recruiting
Trial end date:
2028-03-01
Target enrollment:
Participant gender:
Summary
This project investigates the clinical and biological impact of combining immunotherapy
(pembrolizumab) with short course radiotherapy (5Gy, five times) in the neo-adjuvant
treatment of localised microsatellite stable (MSS) rectal cancer.